On March 16, the President released his budget blueprint for fiscal year (FY) 2018, which proposes deep cuts in funding for federal research at the NIH as well as an increase in FDA user fees.
Last August, State Senator Ed Hernandez (D-Asuza) pulled his drug price reporting legislation — Senate Bill (SB) 1010 — after the bill was amended in the Assembly Appropriations Committee. On March 15, he introduced SB 17, which is a somewhat modified version of last year’s bill.
Leadership of federal departments and agencies with oversight of issues of importance to California’s life sciences sector continue to take shape under the new Trump Administration.
Asm. Jim Wood (D-Healdsburg), Chair of the Assembly Health Committee, is preparing Assembly Bill (AB) 265 (drug coupons) to be heard in his committee at some time in April.
While the County of Los Angeles in Southern California deliberates over take-back legislation, the number of Counties in Northern California to pass take-back ordinances continues to grow.
On Feb. 16, House Republican leadership distributed a policy brief outlining how they intend to go about repealing and replacing the Patient Protection and Affordable Care Act (ACA) originally enacted in 2010.
California Assembly Health Committee Chair, Asm. Jim Wood (D-Healdsburg), has opened this year’s legislative session with drug costs in his crosshairs, introducing two bills and holding hearings related to the subject.
Given the medical device excise tax’s disproportionate impact in California, CLSA has been a leading advocate in support of its full repeal. In the 115th Congress, CLSA continues to advocate for a full and permanent repeal of the medical device excise tax.
CLSA continues to advocate for solutions to the Silicon Valley-Bay Area transportation gridlock as part of the C3 coalition so our member company employees can more easily commute.
With the opening of the 115th Congress, the 55-Member California congressional delegation continues to rank amongst the most influential, with numerous members serving in positions of leadership and on committees with jurisdiction over issues and policies critical to the continued advancement of our state’s and the nation’s life sciences sector.